Prolonged Basiliximab Use as an Alternative to Calcineurin Inhibition to Allow Renal Recovery Late After Heart Transplantation

Journal of Heart and Lung Transplantation

Volumn 27, Issue 9, 2008, Pages 1043-1045

  Anselm, Anjali ^a   Cantarovich, Marcelo ^b   Davies, Ross ^a   Grenon, Jackie ^a   Haddad, Haissam ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ADULT; ARTICLE; CASE REPORT; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT FAILURE; HEART ARREST; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; LEUKOPENIA; MORNING DOSAGE; NEPHROTOXICITY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; TREATMENT DURATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; CALCINEURIN; CARDIOMYOPATHIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEART ARREST; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KIDNEY; KIDNEY FAILURE, ACUTE; POSTOPERATIVE COMPLICATIONS; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, RIGHT; WAITING LISTS;

EID: 50249147368     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2008.04.005     Document Type: Article

References (23)

1. Calne R.Y., Thiru S., McMaster P., et al. Cyclosporine A in patients receiving renal allografts from cadaver donors. Lancet 2 (1978) 1323-1327
2. Rimola A., Gavaler J.S., Schade R.R., et al. Effects of renal impairment on liver transplantation. Gastroenterology 93 (1987) 148-156
3. McGiffin D.C., Kirklin J.K., and Naftel D.C. Acute renal failure after heart transplantation and cyclosporine therapy. J Heart Transplant 4 (1985) 396-399
4. Bennett W.M., DeMattos A., Meyer M.M., Andoh T., and Barry J.M. Chronic cyclosporine nephropathy: the achilles' heel of immunosuppressive therapy. Kidney Int 50 (1996) 1089-1100
5. English J., Evan A., Houghton D.C., and Bennett W.M. Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 44 (1987) 135-141
6. Vincenti F., Grinyo J., Ramos E., et al. Can antibody prophylaxis allow sparing of other immunosuppressives?. Transplant Proc 31 (1999) 1246-1248
7. Hong J.C., and Kahan B.D. A calcineurin-free strategy for induction immunosuppression for delayed graft function in cadaveric kidney transplantation. Transplantation 71 (2001) 1320-1328
8. Chang G.J., Mahanty H.D., Vincenti F., et al. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Clin Transplant 14 (2000) 550-554
9. Cantarovich M., Metrakos P., Giannetti N., et al. Anti-CD25 monoclonal antibody coverage allows for calcineurin inhibitor "holiday" in solid organ transplant patients with acute renal dysfunction. Transplantation 73 (2002) 1169-1172
10. Stewart S., Winters G.L., Fishbein M.C., et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 24 (2005) 1710-1720
11. Nashan B., Moore R., Amlot P., et al. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 350 (1997) 1193-1198
12. Kovarik J.M., Kahan B.D., Rajagopalan P.R., et al. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. Transplantation 68 (1999) 1288-1294
13. Taniguchi T., and Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell 73 (1993) 5-8
14. Kupiec-Weglinski J.W., Diamantstein T., and Tilney N.L. Interleukin 2 receptor-target therapy-rational and applications in organ transplantation. Transplantation 46 (1988) 785-792
15. Vincenti F., Kirkman R., Light S., et al. Interleukin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 338 (1998) 161-165
16. Vincenti F., Pace D., Birnbaum J., and Lantz M. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantion. Am J Transplant 3 (2003) 50-52
17. Potter B., Giannetti N., Cecere R., and Cantarovich M. Long-term calcineurin inhibitor "holiday" using daclizumab in a heart transplant patient with acute renal dysfunction. J Heart Lung Transplant 24 (2005) 1126-1128
18. Cantarovich M, Tchervenkov J, Giannetti N, et al. Long-term calcineurin inhibitor "retirement" with anti-CD25 monoclonal antibodies in non-renal transplant patients with chronic kidney disease. Abstract presented at the American Transplant Congress, San Francisco, CA, 2007.
19. Vincenti F., Ramos E., Brattstrom C., et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 71 (2001) 1282-1287
20. Asberg A., Midtvedt K., Line P.D., et al. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Transplantation 82 (2006) 62-68
21. Levey A.S., Coresh J., Greene T., et al. Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145 (2006) 247-254
22. Edwards N.M., Chen J.M., and Mazzeo P.A. Cardiac transplantation: the Columbia University Medical Center/New York-Presbyterian Hospital manual (2004), Humana Press, Totowa, NJ
23. Lieberthal W., Fuhro R., Andry C., et al. Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 281 (2001) F693-F706